Pharmaceutical manufacturers of Tobramycin

Transo-Pharm, a fully authorized and accredited distributor, specializes in pharmaceutical components for the medical and veterinary sectors. It provides assistance to customers throughout the entire API life cycle, from product innovation to sales. Transo-Pharm acts as a sourcing and regulatory marketing representative for API producers. It assists customers in establishing DMFs and offers GMP advisory services. With a dedicated regulatory division, a storage facility, proprietary IPs for API procedures, and collaborations with research facilities, Transo-Pharm offers a broad array of services. It operates from its establishments in Shanghai, Hong Kong, Singapore, and the United States.

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

Xellia is a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.

Livzon Group is a full-fledged pharmaceutical company that integrates the advancement and exploration, manufacturing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients (API), chemical medication, diagnostic reagents, and more. Recently, Livzon has shifted its strategic focus to research and development in antibody medications and vaccines, and has set up specialized laboratories for this purpose.

Livzon Group Fuzhou Fuxing Pharmaceutical Co Ltd (FFPC) was founded in 1979. Livzon Pharmaceutical Group Inc purchased FFPC in 2004, aiming to transform it into a top-notch API production center and R&D center. FFPC is a sizable pharmaceutical company with two facilities, Gutian Fuxing Pharmaceutical Co., Ltd and Fuqing Jiangyin site. FFPC has state-of-the-art machinery and advanced technology.

Chongqing Daxin Pharmaceutical Co., Ltd. (herein referred as Chongqing Daxin) was established in 1941. It is a core member of PKU HealthCare Industry，which has been praised as the Key High-tech Enterprise of the National Torch Program, Nationwide Key Enterprise in Chemical and Pharmaceutical Industry, one of the National Top 100 Pharmaceutical Enterprises and the Exportation brand leader enterprise supported by Chongqing government. After over 70 year's development, it has become a biotech oriented and comprehensive pharmaceutical company which covers areas of APIs and finished dosages.

Let's transform into a company that offers top-notch solutions for enhancing human well-being and enhancing the quality of life. We aspire to be a pioneering company in the fields of beauty, pharmaceuticals, and bio, generating excitement globally. When I contribute to others, I also benefit myself. Daebong LS is dedicated to producing trustworthy and secure products through ongoing research and development. The Convergence Technology Laboratory fosters innovative R&D through collaboration and joint development.

The Saraf group of enterprises was established by the forward-thinking Shri Mahavir G. Saraf in 1952. Sarex Overseas represents a segment of the Saraf group of corporations, and its primary operations center on being a prominent producer of Fine Chemicals and API Intermediates within India. The corporate headquarters of Sarex Overseas is situated in Mumbai, while its manufacturing facility is located in MIDC, Tarapur, which is approximately 100 kilometers from Mumbai in India. Sarex, which was founded in 2002, has garnered a reputation as a reputable Exporter, Manufacturer, and Supplier in India, focusing on producing Active Pharmaceutical Ingredients (API), Bulk Drug Intermediates, and Veterinary Medicines, including IVERMECTIN EP, among others. The organization's adept team of professionals, under expert guidance, processes all products, and the finished range undergoes thorough scrutiny by quality analysts based on various parameters such as composition, pH value, viscosity, and packaging. The company utilizes top-notch materials for packaging. Sarex specializes in the production of high-quality organic fine chemicals for the pharmaceutical and electronics industries, with a focus on Fridel craft, halogenation, nitration, oxidation, and high-pressure reactions. Notably, Sarex excels in process development and customer synthesis, operates pilot plants, and engages in bulk production of heterocycles like Tetrazoles, Triazines, and Quinazolines, among others. Its multipurpose plants include Glass-lined reactors, Stainless steel reactors, high-pressure reactors, and high vacuum distillation units, all supported by QA, QC, and R&D. The company serves as a supplier to numerous catalogue companies for small and bulk quantities and also provides toll manufacturing for large multinational companies.

Fujian Fukang Pharmaceutical Co., Ltd (Fukang) is located in Fuzhou-capital of Fujian province, founded in 1958, renamed Fuzhou Antibiotic General Factory in 1992 and became a wholly state-owned enterprise in 1996. In 2002 it was reformed into a corporation with a variety of shareholders. Over more than 40 years Fukang is steadily growing. Starting from a single product, its current product range includes 7ACA intermediate, sterile cephalosporin API, antibiotic API, preparation and Animal Feed. As one of the top 100 pharmaceutical enterprises in China in terms of sales volume and profit, Fukang has successfully established and maintained a long-term and sound business relationship with more than 100 companies over the world. Following the sustained development strategy, Fukang invested in a new plant with 285,000 m2 in Jiangyin chemical industry zone, Fuzhou in 2003.

Maiva Pharma initiated its operations in 1996, specializing as a producer of premium liquid sterile formulations in small-volume glass vials and ampoules, as well as large-volume glass bottles. The facility is equipped with 4 manufacturing lines capable of producing both aseptically filled and terminally sterilized products. Maiva holds certifications from EU-GMP, Health Canada, PIC/S, USFDA, ANVISA, and WHO-GMP. Additionally, Maiva has obtained 19 ANDA approvals for the US market. The company possesses the capability to conduct comprehensive pharmaceutical development and manufacturing of sterile liquid and lyophilized vials.